Clinical Research Division, Fred Hutch
Dr. Armin Rashidi studies how the microbiome, the community of bacteria living in and on our bodies, influences patients’ outcomes after intensive therapy for blood cancers. Our health is intimately tied to the health of our microbiomes, and treatment regimens for blood cancers, which can include immune-suppressing chemotherapy and antibiotics to stave off infection, often disrupt these communities. This disruption, or dysbiosis, can open the door to life-threatening infections and influence treatment complications. Rashidi studies how the makeup of individual microbiomes influence how they respond to cancer treatments and how different blood cancer treatments alter the patients’ microbiomes. With these insights, Rashidi hopes to develop better strategies to prevent and treat dysbiosis and improve blood cancer treatment outcomes.
Division of Hematology and Oncology, UW School of Medicine
Hematology and Medical Oncology Fellowship, Washington University in St. Louis, 2016
Internal Medicine Residency, Eastern Virginia Medical School, 2013
PhD, Biogerontology, Newcastle University, Newcastle upon Tyne, 2010
MD, Tehran University of Medical Sciences, 2006
Impact of microbiome on outcomes of intensive therapy in patients with hematologic malignancies